Low frequency of albuminuria testing among diabetic patients in France: Real-world data from clinical laboratories

Diabetes Metab. 2024 Jan;50(1):101498. doi: 10.1016/j.diabet.2023.101498. Epub 2023 Nov 23.

Authors

Fabrice Bonnet¹, Léa Longepierre², Dinh-Phong Nguyen³, Imène Sedrati⁴, Alegria Marcilla⁵

Affiliations

¹ Service Endocrinologie, diabétologie et nutrition du CHU de Rennes, 16 bvd de bulgarie, Rennes 35203, France.
² Kiro, 19 rue du renard, Paris 75004, France. Electronic address: lea@kiro.bio.
³ Kiro, 19 rue du renard, Paris 75004, France.
⁴ AstraZeneca, Tour Carpe Diem, 31 Place des Corolles, Courbevoie 92400, France.
⁵ Département médical AstraZeneca, Tour Carpe Diem, 31 Place des Corolles, Courbevoie 92400, France.

PMID: 38000505
DOI: 10.1016/j.diabet.2023.101498

No abstract available

Publication types

Letter

MeSH terms

Albuminuria / diagnosis
Diabetes Mellitus, Type 2*
Diabetic Nephropathies*
France / epidemiology
Humans
Laboratories, Clinical
Risk Factors